Shanghai Pioneer Holding Ltd (1345) AI Stock Analysis

• Market Cap: HK$2.82B
• Dividend Yield: 5.26%
• Average Volume (3M): 54.17K
• Price to Earnings (P/E): 12.1
• Beta (1Y): 0.12
• Revenue Growth: -17.61%
• EPS Growth: -35.76%
• Country: HK
• Employees: 335
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.04
• Shares Outstanding: 1,257,447,000
• 10 Day Avg. Volume: 73,600
• 30 Day Avg. Volume: 54,166
• PEG Ratio: 2.03
• Price to Book (P/B): 2.31
• Price to Sales (P/S): 1.68
• P/FCF Ratio: 12.35
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: HK$2.50 ▲(11.11% Upside)
• Action: Upgraded Date: 10/29/25
• Date: Action: Upgraded 10/29/25

The stock's overall score is driven by strong financial performance and positive technical indicators. The stable financial health and attractive dividend yield are significant strengths, while the moderate valuation suggests room for growth. The absence of earnings call and corporate events data did not impact the score.

Positive Factors

Low leverage / robust balance sheet

A low debt-to-equity ratio and stable capital structure reduce refinancing and liquidity risk, giving management flexibility to fund R&D, M&A or capital expenditures. This financial strength supports durable operations and resilience through sector cycles over the next 2–6 months.

Rebounding free cash flow

A recovery in free cash flow improves self-funding capacity for operations, strategic investments and shareholder returns while lowering reliance on external financing. Even with some variability, sustained positive cash generation materially strengthens long-term financial flexibility and execution risk.

Stable operational margins

Healthy gross margins and steady EBIT/EBITDA margins point to effective cost control and pricing power across products. Stable operating profitability supports reinvestment, tolerates input cost swings, and underpins sustainable cash conversion and competitive positioning over the medium term.

Negative Factors

Declining revenue trend

A near-term revenue decline of ~17.6% signals material demand or market-share challenges. Persisting revenue contraction reduces scale benefits, pressures margins and free cash flow, and may limit the firm's ability to invest in growth or absorb regulatory and competitive headwinds over the coming months.

EPS contraction

A roughly 35% drop in EPS reflects meaningful profitability pressure that can erode retained earnings and restrict reinvestment or dividends. If EPS weakness persists, it could constrain strategic flexibility and increase scrutiny on cost structure and product profitability over the medium term.

Profitability and cash flow variability

Fluctuating net margins and variable free cash flow-to-income ratios raise forecasting and execution risk. Inconsistent cash conversion complicates capital planning, may increase working-capital needs, and reduces the reliability of dividends or discretionary investments during uncertain industry or demand conditions.

Shanghai Pioneer Holding Ltd Business Overview & Revenue Model

Company Description

China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People's Republic of China. It has a portfolio of pharmaceutical products, such as ophthalmology, pain management, cardiovascular, immunology, gynecology, gastroenterology, and other therapeutic areas, as well as medical devices, including ophthalmology, orthopedics, odontology, and wound care products. The company sells its products to hospitals and medical institutions, and pharmacies. It also sells ancillary tools and leases accessories; and sells dental devices. In addition, the company engages in the sale of imported in-licensed prescription products. China Pioneer Pharma Holdings Limited was founded in 1996 and is headquartered in Shanghai, the People's Republic of China. China Pioneer Pharma Holdings Limited is a subsidiary of Pioneer Pharma (BVI) Co., Ltd.

How the Company Makes Money

Shanghai Pioneer Holding Ltd generates revenue through multiple streams, primarily by manufacturing and selling industrial products, which accounts for a significant portion of its income. The company also earns money through its logistics services, offering transportation and supply chain management solutions to clients across different sectors. Additionally, strategic partnerships with other firms in the manufacturing and technology sectors enable the company to expand its reach and enhance its service offerings, thereby contributing to its revenue growth. The combination of product sales, service contracts, and collaborative ventures ensures a diversified revenue model that supports the company's financial performance.

Shanghai Pioneer Holding Ltd Financial Statement Overview

Summary

Shanghai Pioneer Holding Ltd demonstrates strong financial health with a stable revenue base and operational efficiency. The low leverage enhances financial stability, although there is some variability in profitability and cash flow.

Income Statement

Shanghai Pioneer Holding Ltd shows a consistent revenue base with moderate growth. The gross profit margin is healthy, reflecting efficient cost management. However, the net profit margin has fluctuated, indicating some instability in profitability. The EBIT and EBITDA margins are stable, suggesting solid operational efficiency.

Balance Sheet

The balance sheet is robust, with a low debt-to-equity ratio signifying strong financial health and low leverage. The return on equity indicates efficient use of shareholders’ funds, although there is room for improvement. The equity ratio demonstrates a stable capital structure, providing a solid foundation for future growth.

Cash Flow

The company has shown strong free cash flow growth, rebounding from previous negative figures, which supports operational investments and reduces financial risk. The operating cash flow to net income ratio is positive, indicating good cash conversion. However, fluctuations in free cash flow to net income ratio suggest potential variability in cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.36B	1.53B	1.57B	1.56B	1.43B	1.33B
Gross Profit	635.74M	683.21M	668.24M	780.47M	772.03M	607.97M
EBITDA	197.81M	215.27M	201.88M	245.38M	199.96M	104.79M
Net Income	104.40M	151.62M	145.72M	235.30M	142.63M	52.45M
Balance Sheet
Total Assets	1.41B	1.46B	1.53B	1.57B	1.33B	1.43B
Cash, Cash Equivalents and Short-Term Investments	195.12M	103.57M	124.43M	289.01M	402.08M	254.61M
Total Debt	134.85M	75.22M	74.02M	37.59M	14.05M	15.10M
Total Liabilities	323.03M	342.52M	513.14M	549.18M	417.49M	516.73M
Stockholders Equity	1.08B	1.11B	1.01B	1.01B	907.97M	909.43M
Cash Flow
Free Cash Flow	172.15M	208.01M	-163.24M	19.02M	225.43M	39.37M
Operating Cash Flow	192.84M	214.83M	-118.69M	93.30M	242.06M	74.24M
Investing Cash Flow	-91.02M	-99.76M	69.51M	-12.99M	8.39M	23.93M
Financing Cash Flow	-73.24M	-125.92M	-50.56M	-91.03M	-140.28M	-253.04M

Shanghai Pioneer Holding Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1345, the sentiment is Positive. The current price of 2.25 is below the 20-day moving average (MA) of 2.28, below the 50-day MA of 2.30, and above the 200-day MA of 2.10, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.68 is Neutral, neither overbought nor oversold. The STOCH value of 90.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1345.

Shanghai Pioneer Holding Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1345	74 Outperform	HK$2.82B	12.14	9.43%	5.26%	-17.61%	-35.76%
2348	72 Outperform	HK$1.74B	4.06	5.34%	5.16%	2.89%	-68.83%
2633	69 Neutral	HK$2.43B	5.13	12.97%	15.40%	-1.88%	17.57%
2219	68 Neutral	HK$1.81B	4.06	7.31%	9.29%	-3.19%	-20.30%
1110	56 Neutral	HK$303.25M	-13.32	0.86%	5.87%	-10.78%	-82.81%
3390	53 Neutral	HK$254.79M	-9.36	-4.89%	28.00%	-1.68%	-111.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%